Avalo Therapeutics Inc (AVTX) — Cash Flow Reinvestment Rate

Latest as of September 2022: 0.01x

Avalo Therapeutics Inc (AVTX) has a Cash Flow Reinvestment Rate of 0.01x as of September 2022, reinvesting $78.00K (capex $39.00K plus investments $-39.00K) from operating cash flow of $5.73 Million. See AVTX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.01x
(Capex + Investments) / Operating CF

Total Reinvested

$78.00K
Capex + Investments

Operating Cash Flow

$5.73 Million
USD

Capital Expenditures

$39.00K
USD

Avalo Therapeutics Inc Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for Avalo Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see Avalo Therapeutics Inc cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Avalo Therapeutics Inc (2017–2017)

Year-by-year capital reinvestment analysis for Avalo Therapeutics Inc. See AVTX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2017 1.03x $12.86 Million $12.52 Million $23.32K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow